Filtered By:
Cancer: Chronic Lymphocytic Leukemia

This page shows you your search results in order of relevance. This is page number 14.

Order by Relevance | Date

Total 209 results found since Jan 2013.

Management of hypogammaglobulinemia and recurrent infections in a chronic lymphocytic leukemia patient receiving ibrutinib
Chronic lymphocytic leukemia (CLL) is a chronic lymphoproliferative disorder characterized by the progressive accumulation of monoclonal and functionally incompetent lymphocytes; it also is the most common adult leukemia in Western countries.1 In CLL, hypogammaglobulinemia is the predominant inherent immune defect and is often further exacerbated by immunosuppressive treatment.2 Nevertheless, neither antibiotic prophylaxis nor prophylactic immunoglobulin (Ig) replacement therapy (IRT) is routinely recommended for CLL.
Source: Annals of Allergy, Asthma and Immunology - November 23, 2017 Category: Allergy & Immunology Authors: Fonda Jiang, Prashant Verma Tags: Letter Source Type: research

Resolution of Eosinophilia and Elevated Immunoglobulin E with Ibrutinib for Chronic Lymphocytic Leukemia
We describe a case of eosinophil ia and elevated IgE in a 61-year-old gentleman who was subsequently diagnosed with B-cell chronic lymphocytic leukemia (B-CLL). His eosinophilia and immunoglobulin E (IgE) levels declined significantly after initiating ibrutinib therapy for B-CLL.
Source: Annals of Allergy, Asthma and Immunology - July 15, 2018 Category: Allergy & Immunology Authors: Kaoru Harada, Joel P. Brook, Francis M. Lobo Tags: Letters Source Type: research

Complement C5b-9 and Cancer: Mechanisms of Cell Damage, Cancer Counteractions, and Approaches for Intervention
In conclusion, osmotic burst of inflated complement-damaged cells may occur, but these bursts are most likely a consequence of metabolic collapse of the cell rather than the cause of cell death. The Complement Cell Death Mediator: A Concerted Action of Toxic Moieties Membrane pores caused by complement were first visualized by electron microscopy on red blood cell membranes as large ring structures (22). Similar lesions were viewed on E. coli cell walls (23). Over the years, ample information on the fine ultrastructure of the MAC that can activate cell death has been gathered (24) and has been recently further examined (...
Source: Frontiers in Immunology - April 9, 2019 Category: Allergy & Immunology Source Type: research

Beyond CAR T Cells: Other Cell-Based Immunotherapeutic Strategies Against Cancer
Conclusions: CAR T cell therapies have demonstrated the clinical benefits of harnessing our body's own defenses to combat tumor cells. Similar research is being conducted on lesser known modifications and gene-modified immune cells, which we highlight in this review. Introduction Chimeric antigen receptors and engineered T cell receptors (based on previously identified high affinity T cell receptors) function by redirecting T cells to a predefined tumor-specific (or tumor-associated) target. Most of these modifications use retroviral or lentiviral vectors to integrate the construct, and most of the receptors ...
Source: Frontiers in Oncology - April 9, 2019 Category: Cancer & Oncology Source Type: research

B Cell Reconstitution and Influencing Factors After Hematopoietic Stem Cell Transplantation in Children
Nicolaas G. van der Maas, Dagmar Berghuis, Mirjam van der Burg and Arjan C. Lankester* Willem-Alexander Children's Hospital, Department of Pediatrics and Laboratory for Pediatric Immunology, Leiden University Medical Center, Leiden, Netherlands B cell reconstitution after hematopoietic stem cell transplantation (HSCT) is variable and influenced by different patient, donor, and treatment related factors. In this review we describe B cell reconstitution after pediatric allogeneic HST, including the kinetics of reconstitution of the different B cell subsets and the development of the B cell repertoire, and d...
Source: Frontiers in Immunology - April 11, 2019 Category: Allergy & Immunology Source Type: research

TRAIL-R1 and TRAIL-R2 Mediate TRAIL-Dependent Apoptosis in Activated Primary Human B Lymphocytes
In conclusion, this study provides a systematic analysis of the expression of TRAIL-Rs in human primary B cells and of their capacity to signal and induce apoptosis. This dataset forms a basis to further study and understand the dysregulation of TRAIL-Rs and TRAIL expression observed in autoimmune diseases. Additionally, it will be important to foresee potential bystander immunomodulation when TRAIL-R agonists are used in cancer treatment. Introduction The homeostasis of humoral immunity requires a tight control of generation, survival, activation and maturation of B lymphocytes. Therefore, pro-survival and pro-apo...
Source: Frontiers in Immunology - April 29, 2019 Category: Allergy & Immunology Source Type: research

M255 persistent hypogammaglobulinemia following obinutuzumab treatment for chronic lymphocytic leukemia
We report a patient who completed obinutuzumab treatment, a type 2 anti-CD20 monoclonal antibody, for chronic lymphocytic leukemia (CLL) with resulting symptomatic hypogammaglobulinemia.
Source: Annals of Allergy, Asthma and Immunology - October 31, 2019 Category: Allergy & Immunology Authors: M. Hauk, B. McGoey, M. Michelis Source Type: research

A250 humoral immunodeficiency in patients with chronic lymphocytic leukemia
Patients with chronic lymphocytic leukemia (CLL) are at increased risk of infections as compared to age matched controls, and infections are a major cause of morbidity and mortality. Although hypogammaglobinemia occurs with CLL, there is minimal data regarding vaccine responses in these patients. We characterized immunoglobulin (Ig) levels and vaccine responses in patients with CLL.
Source: Annals of Allergy, Asthma and Immunology - October 31, 2019 Category: Allergy & Immunology Authors: S. Mustafa, S. Jamshed, A. Ramsey Tags: Clinical Immunology, Immunodeficiency Source Type: research

Three-Drug Combo Promising Against High-Risk CLL Three-Drug Combo Promising Against High-Risk CLL
The combination of obinutuzumab, ibrutinib, and venetoclax was associated with a high complete response rate in patients with high-risk chronic lymphocytic leukemia, a phase 2 trial finds.Medscape Medical News
Source: Medscape Allergy Headlines - June 15, 2020 Category: Allergy & Immunology Tags: Hematology-Oncology News Alert Source Type: news

Skin testing with bendamustine: what concentration should be used?
We present a case of the patient, who developed hypersensitivity reaction during the treatment of chronic lymphocytic leukemia. Bendamustine was suspected as a culprit agent. The patient as well as 3 controls ...
Source: Allergy, Asthma and Clinical Immunology - July 30, 2020 Category: Allergy & Immunology Authors: Laura Malinauskiene, Kestutis Cerniauskas, Kotryna Linauskiene, Linas Griguola, Anzelika Chomiciene and Audra Blaziene Tags: Letter to the editor Source Type: research

M079 a case of chronic lymphocytic leukemia unveiled in a patient presenting with eosinophilia
We present a case of chronic lymphocytic leukemia (CLL) uncovered by CBC obtained to phenotype asthma.
Source: Annals of Allergy, Asthma and Immunology - November 1, 2021 Category: Allergy & Immunology Authors: A. Chastant, M. Le, E. Atkinson Source Type: research

CD8+ T-cells Co-expressing PD-1 and TIGIT Are Highly Frequent in Chronic Lymphocytic Leukemia
Iran J Allergy Asthma Immunol. 2021 Dec 8;20(6):751-763. doi: 10.18502/ijaai.v20i6.8027.ABSTRACTThe role of immune checkpoint receptors in T-cell exhaustion has been demonstrated in several cancers. We investigated the co-expression of TIGIT/PD-1 and LAG-3/PD-1 cells in patients with chronic lymphocytic leukemia (CLL). The frequencies of TIGIT+PD-1+CD8+and LAG-3+PD-1+CD8+cells and relative mRNA expression of LSECtin and CD155 were examined in PBMCs from 33 CLL patients and 20 controls. The percentage of TIGIT+PD-1+CD8+cells was significantly higher in CLL patients than in control subjects, with the preference in advanced s...
Source: Cancer Control - December 18, 2021 Category: Cancer & Oncology Authors: Reza Hajiasghar-Sharbaf Hossein Asgarian-Omran Reza Valadan Hadi Hossein-Nattaj Ramin Shekarriz Ehsan Zaboli Ghasem Janbabaei Mohsen Tehrani Source Type: research

CLL Patients ' Cured ' : 10 Years Post-Infusion, CAR T Cells Persist CLL Patients ' Cured ' : 10 Years Post-Infusion, CAR T Cells Persist
Two patients with chronic lymphocytic leukemia who were among the first to receive the groundbreaking therapy were still in remission a decade later.Medscape Medical News
Source: Medscape Allergy Headlines - February 3, 2022 Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news

IL-25 Impact on Malignant B Cells Survival and T Cells Activation in Chronic Lymphocytic Leukemia
Iran J Allergy Asthma Immunol. 2023 Jun 16;22(3):299-311. doi: 10.18502/ijaai.v22i3.13058.ABSTRACTT cell dysregulation and shift to T helper 2 responses, boosting tumor microenvironment support, contributes to the survival of leukemic B cells in Chronic Lymphocytic Leukemia. Interleukin (IL)-25 is involved in the initiation of T helper 2 cell responses. Signal transduction of IL-25 begins with the heterodimer receptor (IL-17RA/IL-17RB). The presence of IL-25 in the tumor microenvironment may affect the supportive effects of T cells in the surrounding tumor cell environment. The purpose of this study was to evaluate the rol...
Source: Cancer Control - July 31, 2023 Category: Cancer & Oncology Authors: Mehrnoosh Pashei Farahnaz Ghahremanfard Ehsan Manouchehri Doulabi Maral Hemmati Fatemeh Pak Parviz Kokhaei Source Type: research